Research / Projects

Second Programme of Community action in the Field of Health 2008-2013
UNEW_FY2013 [UNEW_FY2013]
TREAT-NMD is an international network for rare inherited neuromuscular disorders (NMDs). Its mission is to provide an infrastructure to increase collaboration between clinicians, scientists, and patie...
TREAT-NMD is an international network for rare inherited neuromuscular disorders (NMDs). Its mission is to provide an infrastructure to increase collaboration between clinicians, scientists, and patients, accelerate therapy development for these incurable conditions, improve patient care through publication and dissemination of best-practice consensus guidelines, and provide reliable information for patients and professionals. TREAT-NMD was established in 2007, and until the end of 2011, was funded through FP6 to bring together stakeholders representing all NMDs (>200 diseases). Although NMDs are individually rare, TREAT-NMD activities address ~200,000 patients in the EU, and ~3 million worldwide.
Since 2007 TREAT-NMD has increased the collaborating capacity of the field, raised the profile of NMDs within the wider rare disease (RD) field, become a model for RD collaboration, and increased the profile of European NMD research and healthcare globally. A public consultation in 2010 strongly endorsed the continuation and further development of TREAT-NMD`s core activities.
The TREAT-NMD Alliance has extended beyond the original network members to integrate new participants from around the world. The original number of ~350 scientists and clinicians that were integrated into the network through the 22 partners has now more than doubled and constitutes a critical mass for innovation and harmonisation in NMD care and research globally.
TREAT-NMD outputs:
-highly developed communication/dissemination infrastructure with extensive website and newsletter
-network of over 270 NMD care and trial sites
-global patient registries for several NMDs with >20,000 patients
-range of preclinical resources
-tools supporting translational & clinical research
TREAT-NMD vision:
-enhance European excellence in the NMD field
-increase visibility & recognition of NMDs in national health policy
-sustain core resources and added value of networking developing tools that cannot be maintained by individual research projects
-extend networking activities and resources to new experts worldwide
Start date: 01/01/2013 - End date: 01/01/2014

Call: Generate And Disseminate Health Information And Knowledge (Hi-2012)
Topic: Research
Second Programme of Community action in the Field of Health 2008-2013
Safety evaluation of manufactured nanomaterials by characterisation of their potential genotoxic hazard [NANOGENOTOX]
Human exposure to manufactured nanomaterials (MNs) used in consumer products may occur during several phases of their life cycle. The lack of scientific knowledge makes regulation difficult.

The aim ...
Human exposure to manufactured nanomaterials (MNs) used in consumer products may occur during several phases of their life cycle. The lack of scientific knowledge makes regulation difficult.

The aim of the Joint Action is to establish a robust methodology to assess the potential genotoxicity of MNs and to generate data on the genotoxic effect of certain reference materials (www.nanogenotox.eu).

The JA specific objectives are:
To obtain detailed physicochemical properties for each selected MN
To determine the influence of exposure media on MNs dispersability and to identify the optimum preparation protocols for the specific MNs
To generate in vitro genotoxicity data on MNs
To perform a round robin test on in vitro genotoxicity testing of MNs
To determine relevant doses and sampling time for biodistribution and in vivo genotoxicity studies, and to identify MN accumulation in organs for in vivo genotoxicity tests
To generate data from in vivo genotoxicity selected tests, and to assess the correlation between in vivo and in vitro results taking into account the kinetic results
Start date: 01/03/2010 - End date: 01/03/2013

Call: Improve Citizen''S Health Security (Hs-2009)
Topic: Research
Second Programme of Community action in the Field of Health 2008-2013
Innovating care for people with multiple chronic conditions in Europe [ICARE4EU]
The project ICARE4EU aims to contribute to the innovation of care for European citizens with multiple chronic conditions by increasing and disseminating knowledge of potentially effective and efficien...
The project ICARE4EU aims to contribute to the innovation of care for European citizens with multiple chronic conditions by increasing and disseminating knowledge of potentially effective and efficient models of integrated care for people with multiple chronic conditions that are developed and implemented in (parts of) European countries. The vast majority of people with multimorbidity are older individuals. Integrated care addresses their integral needs for health and social care, and is provided by multidisciplinary teams of professionals and/or informal carers.
ICARE4EU will describe the state of the art in 30 European countries; evaluate the strengths and weaknesses of current integrated care programmes; identify best practices from different perspectives; generate knowledge about key characteristics and conditions for successful management and implementation of integrated care programmes; design a template for future monitoring of the developments in multimorbidity chronic illness care; and disseminate its findings throughout Europe.

Start date: 01/03/2013 - End date: 01/08/2016

Call: Promote Health (Hp-2012)
Topic: Research
Second Programme of Community action in the Field of Health 2008-2013
European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment [ExPO-r-NeT]
This project will build a Paediatric Oncology (PO) European Reference Network (ERN) providing paramount requirements for ‘Cross-border healthcare’ allowing the provision of healthcare to children ...
This project will build a Paediatric Oncology (PO) European Reference Network (ERN) providing paramount requirements for ‘Cross-border healthcare’ allowing the provision of healthcare to children and young people with cancer in a Member State other than the Member State of affiliation. It will identify target groups with conditions that require a particular concentration of resources or expertise, especially when the expertise with certain cancer conditions is rare and case volume low. EXPO-r-NeT aims to reduce current inequalities in childhood cancer survival and healthcare capabilities in different member states. The main objective is to establish a PO-ERN linking pre-existing reference centres inherent to the Cooperative PO- Clinical Trial Groups which may contribute high-level diagnostic and medical expertise to provide cross-border best care to rare childhood cancer populations.
Start date: 01/03/2014 - End date: 01/03/2017

Call: Promote Health (Hp-2013)
Topic: Research
3rd Health Programme (2014-2020)
EUROPEAN REFERENCE NETWORK ON RARE HEMATOLOGICAL DISEASES [ERN-EuroBloodNet]
ERN-EuroBloodNet main goal is to improve the healthcare and overall quality of life of patients with a rare hematological disease (RHD) by facilitating best practice sharing for safe and high-quality ...
ERN-EuroBloodNet main goal is to improve the healthcare and overall quality of life of patients with a rare hematological disease (RHD) by facilitating best practice sharing for safe and high-quality cross-border healthcare and developing more evidence based clinical tools and cost-effective treatments. As a contribution to the 3rd Health Programme (objective 4-Facilitate access to better and safer healthcare for EU citizens), EuroBloodNet will aim at decreasing current cross-border health barriers. EuroBloodNet gathers 66 highly skilled multidisciplinary healthcare teams in 15 Member States, and advanced specialised medical equipment and infrastructures which will facilitate concentration of resources for the design, validation and implementation of high-quality and cost-effective services aimed at facing the challenges of RHD. Involvement from the outset of patient associations will contribute to patient empowerment, in keeping with EuroBloodNet patient-centred approach. EuroBloodNet’s objectives will be achieved through a) the implementation of a reliable repository of best healthcare services available across EU, guidelines for RHD, systematic assessment of clinical outcome indicators, assessment and promotion of ongoing clinical trials and collaborative research initiatives, and b) the development of inter-professional consultation systems and blended (on-site & on-line) educational programmes and short stays. Expected outcomes include reduction of healthcare inequalities for RHD in the EU by a)establishing a cross-border referral system allowing safe information, samples and patient mobility, b) provision of equal access to highly specialised procedures and innovative therapies resulting from best practice sharing, continuous medical education and virtual interprofessional consultation for complex RHD cases, and c)facilitation of a timely and efficient translation of research results into patient oriented strategy at the clinical and the public health level
Start date: 01/03/2017 - End date: 28/02/2018

Call: EUROPEAN REFERENCE NETWORKS SPECIFIC GRANT AGREEMENTS COVERING YEAR 2017
Topic: Research